Twist Bioscience (TWST): Positioning for an EBITDA Inflection on AI-Driven Demand
Key Takeaways
- Profit inflection ahead: Management has reiterated its target to reach adjusted EBITDA breakeven in the fiscal fourth quarter of 2026, with profitability expected in fiscal 2027.
- AI-enabled discovery is the core growth engine: Twist projects triple-digit-percentage order growth for AI-enabled drug discovery in fiscal 2026 and again in fiscal 2027.
- New product cycle underway: The recent launch of Complex Genes extends the company's reach into hard-to-synthesize DNA sequences used in drug discovery and nucleic-acid therapeutics.
- Analyst sentiment is constructive but dispersed: Consensus skews toward Buy, yet published price targets range widely, reflecting differing views on valuation after a substantial share-price run.
- Macro and funding sensitivity: Demand from biopharma, diagnostics, and academic customers ties the outlook to capital-markets conditions, interest rates, and R&D budgets.
- Key risks: Ongoing GAAP net losses, cash burn, and competitive pressure in synthetic biology and next-generation sequencing remain central watch items.
Strategic Positioning and Competitive Landscape
Twist Bioscience operates around a proprietary semiconductor-based DNA synthesis platform that leverages silicon chips to produce DNA at scale. This technology delivers structural advantages in cost, speed, and throughput that support nearly every product line. The business is reported in two primary segments: DNA Synthesis & Protein Solutions, covering synthetic genes and therapeutic antibody discovery, and Next-Generation Sequencing Applications, which provides target-enrichment panels, reagents, and enzymes for genetic analysis.
The investment case centers on biology becoming increasingly digital and data-driven. As pharmaceutical firms, AI-focused biotech companies, and large technology players turn to artificial intelligence and machine-learning models for designing and screening therapeutic candidates, they need large volumes of precisely made DNA. Twist's ability to convert digital designs into physical biological material quickly places it as an important supplier in these design-build-test-learn cycles. A high-throughput new-product introduction process helps convert customer demand into scalable offerings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Competition includes other contract DNA and protein providers as well as established NGS toolmakers. The moat lies in cost leadership, turnaround speed, and manufacturing scale, though pricing power and margin durability will face tests as the markets mature.
Major Catalysts on the Horizon
Several upcoming catalysts could influence investor views in the quarters ahead:
- Fiscal 2026 fourth-quarter results (expected around November 2026): The company guided to fourth-quarter revenue of $123–$124 million, roughly 25% year-over-year growth, and reaffirmed its goal of adjusted EBITDA breakeven in the quarter. Meeting that target would represent a notable strategic shift.
- Fiscal 2027 guidance: Management intends to provide a robust full-year outlook in November, with plans to maintain positive adjusted EBITDA and sequential margin improvement. This update will receive close attention.
- AI-enabled discovery order growth: Twist anticipates triple-digit order growth in both fiscal 2026 and fiscal 2027. Evidence of repeat business and broader customer reach would support the staying power of this driver.
- Complex Genes commercialization: Early-access customers placed more than 1,800 constructs across over 100 orders. A wider rollout could increase wallet share with existing pharma and biotech clients.
- Analyst rating and price-target activity: Ratings have moved in a constructive direction, with recent target increases from firms including Barclays, TD Cowen, Canaccord Genuity, and Guggenheim, along with new coverage starts. A wide dispersion in targets remains, however, showing differing views on valuation.
The consensus rating sits at Buy or Moderate Buy. Price targets nevertheless cover a broad range, with some well below and others well above the recent share price, and several still implying meaningful downside after the stock's strong run. This spread indicates the market is balancing solid operational momentum against a stretched valuation and profitability that is still early.
Industry and Macroeconomic Influences
Twist's path is closely linked to biopharma R&D spending and wider genomics adoption. Interest rates and capital-market conditions matter because many early-stage biotech customers rely on venture or public equity financing and remain sensitive to the cost of capital. A supportive funding backdrop tends to lift demand for Twist's services, while tighter conditions can shrink budgets and extend sales cycles.
Inflation and labor-cost trends affect both the company's expense base and customer spending. Twist has achieved roughly a 60% reduction in manufacturing costs and a 70% reduction in waste over three years, supporting progress toward a long-term gross-margin target above 60%. Geopolitical and supply-chain factors also play a role given the global footprint across the Americas, EMEA, and APAC.
On the technology side, the ongoing shift toward AI-native drug discovery, declining sequencing costs, and growing clinical use of molecular diagnostics, including tumor-informed residual disease testing, represent structural tailwinds aligned with the platform.
2026 Outlook and Longer-Term Themes
Looking toward fiscal 2027 and beyond, the key question is whether Twist can translate rapid revenue growth into sustained, expanding profitability. Management has described fiscal 2026's adjusted EBITDA breakeven as the foundation for disciplined execution, with profitability targeted in fiscal 2027 and a longer-term goal of more than doubling organic revenue by 2031.
Several themes will shape that trajectory. First, AI-enabled drug discovery needs to evolve from an emerging opportunity into a repeatable, multi-year growth engine through continued customer adoption and larger, more predictable orders. Second, margin durability will depend on further manufacturing efficiency gains and a mix shift toward higher-value synthetic biology and therapeutic work. Third, the NGS business offers an adjacent growth path through expansion into molecular diagnostics, proprietary enzymes, and workflow optimization as global sequencing volumes increase.
Capital allocation will stay in focus. With roughly $167 million in cash, cash equivalents, and short-term investments as of mid-2026, Twist maintains flexibility, but ongoing GAAP losses mean investors will monitor whether revenue and margin progress reduce the need for future financing. Competitive pressures from larger, well-capitalized players and regulatory developments affecting diagnostics and drug development complete the list of items to watch.
Consensus expectations reflect optimism on growth alongside continued caution on valuation and the pace of profitability. From what I see, this remains an area where operational delivery will be decisive.
Exploring AI-Driven Forecasting Tools
In my own research process, I turned to Tickeron's Trend Prediction Engine to gain a data-driven perspective on short- and medium-term direction for holdings like this one. The tool provides AI-powered forecasts on whether an asset may trend bullish, bearish, or sideways over the coming week or month, along with historical context and alert features that help evaluate potential breakouts or reversals. I find it useful for complementing fundamental analysis when assessing momentum across a range of instruments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TWST's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Indicator for TWST moved out of overbought territory on October 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 instances where the indicator moved out of the overbought zone. In 42 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 71 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TWST turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
TWST moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 233 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 186 of 228 cases where TWST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.738) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (437.542).
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology
Advertisement